Syndax Announces Compelling Revuforj(R) (revumenib) and Niktimvo(TM) (axatilimab-csfr) Data Accepted for Presentation at ASH 2025 GlobeNewswire November 03, 2025 – 12 revumenib and 11 axatilimab abstracts accepted, including 6 oral presentations, underscoring Syndax's leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in multiple acute leukemia subtypes across the R/R, […]

(NASDAQ:AUTL), LONDON and GAITHERSBURG, Md., Nov. 03, 2025 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces the online publication of five abstracts submitted to the American Society of Hematology (ASH) Annual Meeting, to be held December 6-9, 2025, in Orlando,

(NASDAQ:SNTI), Two presentations, including one oral session, build on existing data and show deep and durable clinical remission rates, combined with a strong safety profile, for SENTI-202 in treating relapsed/refractory Acute Myeloid Leukemia (AML) Pharmacodynamic data further underscore clinical proof-of-mechanism for 'OR/NOT' Logic Gate, showing selective killing of leukemic blasts and leukemic stem cells (LSCs)

(NASDAQ:TERN), Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient population Encouraging safety and tolerability profile at all doses evaluated Company to host investor update call on December 8th at 4:30pm ET FOSTER CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (Terns or the

Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting GlobeNewswire November 03, 2025 Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient population Encouraging safety and tolerability profile at all doses evaluated Company to host

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025 GlobeNewswire November 03, 2025 LONDON and GAITHERSBURG, Md., Nov. 03, 2025 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces the online publication of

Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025 GlobeNewswire November 03, 2025 Two presentations, including one oral session, build on existing data and show deep and durable clinical remission rates, combined with a strong safety profile, for SENTI-202

(NASDAQ:ALLO), SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T(TM)) products for cancer and autoimmune disease, today announced that a Trial-in-Progress (TIP) poster highlighting the pivotal Phase 2 ALPHA3 trial evaluating cemacabtagene ansegedleucel (cema-cel) will be

Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting GlobeNewswire November 03, 2025 SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T(TM)) products for cancer and autoimmune disease, today announced that a Trial-in-Progress (TIP)

QUINCY, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) — Thanksgiving is meant to be a time of comfort, connection, and full plates, but for too many families, it's a season of tough choices. 1 in 7 people in America face hunger, including 1 in 5 children, according to Feeding America. With the prolonged government shutdown and